Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) major shareholder Morningside Venture Investment sold 6,114 shares of the company's stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $6.79, for a total value of $41,514.06. Following the completion of the sale, the insider now directly owns 5,872,993 shares of the company's stock, valued at $39,877,622.47. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.

Morningside Venture Investment also recently made the following trade(s):

• On Thursday, January 12th, Morningside Venture Investment sold 5,000 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.77, for a total value of $33,850.00.
• On Thursday, January 5th, Morningside Venture Investment sold 12,162 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.97, for a total value of $84,769.14.

Kezar Life Sciences Stock Down 1.7 %

NASDAQ KZR traded down $0.11 during trading hours on Thursday, reaching $6.25. 366,771 shares of the company's stock were exchanged, compared to its average volume of 720,273. The company's 50-day moving average is $7.10 and its two-hundred day moving average is $8.39. Kezar Life Sciences, Inc. has a one year low of $4.30 and a one year high of $18.55. The company has a debt-to-equity ratio of 0.03, a quick ratio of 31.15 and a current ratio of 31.15. The company has a market capitalization of $427.36 million, a price-to-earnings ratio of -6.28 and a beta of 0.23.

Hedge Funds Weigh In On Kezar Life Sciences

Large investors have recently bought and sold shares of the company. Great West Life Assurance Co. Can acquired a new position in Kezar Life Sciences during the 3rd quarter worth approximately $26,000. Amalgamated Bank acquired a new position in Kezar Life Sciences during the 1st quarter worth approximately $70,000. Tower Research Capital LLC TRC boosted its position in Kezar Life Sciences by 88.9% during the 3rd quarter. Tower Research Capital LLC TRC now owns 6,777 shares of the company's stock worth $58,000 after acquiring an additional 3,190 shares during the last quarter. Robeco Institutional Asset Management B.V. acquired a new position in Kezar Life Sciences during the 3rd quarter worth approximately $68,000. Finally, UBS Asset Management Americas Inc. acquired a new position in Kezar Life Sciences during the 3rd quarter worth approximately $86,000. Institutional investors and hedge funds own 84.03% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wells Fargo & Company lowered their target price on Kezar Life Sciences from $17.00 to $14.00 and set an "overweight" rating for the company in a research note on Tuesday, January 3rd.

Kezar Life Sciences Company Profile

(Get Rating)

Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.

Featured Articles

• Get a free copy of the StockNews.com research report on Kezar Life Sciences (KZR)
• High-Dividend-Yielding BHP Sees China Driving '23 Growth
• Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
• Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
• Microsoft Layoffs Signal Layoffs for Other Tech Companies?
• More Than One Reason To Buy Fastenal, Quickly

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.